---
title: "ATCO.MED.B.090 Oncology — ANNEX IV – PART ATCO.MED – MEDICAL REQUIREMENTS FOR AIR TRAFFIC CONTROLLERS, ATCO · Avioverse"
description: "After diagnosis of primary or secondary malignant disease, applicants shall be referred to the licensing authority and shall undergo satisfactory…"
url: "https://avioverse.aero/regulations/easa/atco/part-atco-med-medical-requirements-for-air-traffic/subpart-b/atco-med-b-090"
---

# ATCO.MED.B.090 Oncology

ANNEX IV – PART ATCO.MED – MEDICAL REQUIREMENTS FOR AIR TRAFFIC CONTROLLERS · Regulation (EU) 2015/340 · EAR revision 14 Jun 2024

IR Implementing rule

## ATCO.MED.B.090 Oncology

(a) After diagnosis of primary or secondary malignant disease, applicants shall be referred to the [licensing authority](https://avioverse.aero/glossary/easa/licensing-authority) and shall undergo satisfactory oncological evaluation before a fit [assessment](https://avioverse.aero/glossary/easa/assessment) may be considered.

(b) Applicants with an established history or clinical diagnosis of an intracerebral malignant tumour shall be assessed as unfit.

IR · ATCO.MED.B.090 — Regulation (EU) 2015/340 · ATCO Easy Access Rules · EAR revision 14 Jun 2024

AMC Acceptable means of compliance

## AMC1 ATCO.MED.B.090 Oncology

(a) Applicants who have been diagnosed with a malignant disease may be assessed as fit provided:

(1) after primary treatment there is no evidence of residual malignant disease likely to interfere with the safe exercise of the privileges of the [licence](https://avioverse.aero/glossary/easa/licence);

(2) time appropriate to the type of tumour has elapsed since the end of primary treatment;

(3) the risk of incapacitation from a recurrence or metastasis is sufficiently low;

(4) there is no evidence of short- or long-term sequelae from treatment. Special attention should be paid to applicants who have received anthracycline chemotherapy;

(5) satisfactory oncology follow-up reports are provided to the [licensing authority](https://avioverse.aero/glossary/easa/licensing-authority).

(b) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit.

(c) Applicants with a benign intracerebral tumour may be assessed as fit after satisfactory specialist and neurological evaluation and the condition does not compromise the safe exercise of the privileges of the licence.

(d) Applicants with pre-malignant conditions may be assessed as fit if treated or excised as necessary and there is a regular follow-up.

AMC · AMC1 ATCO.MED.B.090 — Regulation (EU) 2015/340 · ED Decision 2015/010/R · ATCO Easy Access Rules · EAR revision 14 Jun 2024

[All rules in SUBPART B – SPECIFIC REQUIREMENTS FOR CLASS 3 MEDICAL CERTIFICATES](https://avioverse.aero/regulations/easa/atco/part-atco-med-medical-requirements-for-air-traffic/subpart-b)

Consolidated from the EASA Easy Access Rules (revision 14 Jun 2024, extracted 13 Oct 2026) for convenience. Not the official publication — verify against the Official Journal of the European Union and the EASA publications before operational use.